URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker, and Moderna’s mRNA ambitions enter a new phase despite years of setbacks.
Plus: Clive Meanwell sees AI’s biggest opportunity in the macro processes of biotech drug design, as opposed to the bespoke making of molecules.
Please follow us:
